Overview

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2021-11-07

Target enrollment:

Participant gender:

Summary

This is a Phase 1b open-label study of ciforadenant, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy in combination with daratumumab, a monoclonal antibody targeting CD38, in relapsed or refractory multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Treatments:

Antibodies, Monoclonal
Daratumumab